NASDAQ · CBLL
CeriBell, Inc.
$27.82+$0.60 (+2.2%)
CeriBell, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
Loading market information…
NASDAQ · TMCI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Treace Medical Concepts, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Treace Medical Concepts, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Treace Medical Concepts, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.25+19.35% vs estimate | $52.57M+6.16% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.01+75.0% vs estimate | $68.71M+2.26% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.25+7.41% vs estimate | $45.09M-32.65% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.82+$0.60 (+2.2%)
CeriBell, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
$14.87+$0.22 (+1.5%)
Bioventus Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.44% below the high.
$31.52+$0.72 (+2.34%)
OrthoPediatrics Corp.’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
$13.80+$0.01 (+0.07%)
Enhabit, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.95% below the high.
$42.98+$0.15 (+0.35%)
Surmodics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.06% below the high.
$5.13-$1.26 (-19.72%)
The Oncology Institute, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
$7.52-$0.12 (-1.51%)
Evolus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.23% below the high.
$20.33-$1.04 (-4.87%)
Semler Scientific, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.19% below the high.
